Congenital myasthenic syndromes

Seminars in Neurology

Volumn 24, Issue 1, 2004, Pages 111-123

  Harper, C Michel ^a,b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

Acetylcholine receptor; Acetylcholinesterase; Choline acetyltransferase; Congenital myasthenic syndromes; Fast channel; Myasthenia gravis; Slow channel

Indexed keywords

3,4 DIAMINOPYRIDINE; ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; EPHEDRINE; FLUOXETINE; NEUROMUSCULAR BLOCKING AGENT; PYRIDOSTIGMINE; QUINIDINE;

CLINICAL FEATURE; CONGENITAL ACETYLCHOLINE RECEPTOR DEFICIENCY; CONGENITAL ACETYLCHOLINESTERASE DEFICIENCY; CONGENITAL CHOLINE ACETYLTRANSFERASE DEFICIENCY; CONGENITAL FAST CHANNEL MYASTHENIC SYNDROME; CONGENITAL MYASTHENIC SYNDROME; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; EATON LAMBERT SYNDROME; ENZYME DEFICIENCY; GENE; GENE MUTATION; GENETIC DISORDER; HUMAN; IMMUNOTHERAPY; MOLECULAR GENETICS; MUSCLE BIOPSY; MYASTHENIA; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; PATHOGENESIS; PRIORITY JOURNAL; RAPSN GENE; REVIEW; SLOW CHANNEL CONGENITAL MYASTHENIC SYNDROME; SODIUM CHANNEL MYASTHENIC SYNDROME; SYNDROME DELINEATION;

ACETYLCHOLINESTERASE; CHOLINE O-ACETYLTRANSFERASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; ION CHANNELS; MUTATION; MYASTHENIC SYNDROMES, CONGENITAL; NEUROMUSCULAR JUNCTION; RECEPTORS, NICOTINIC;

EID: 3042601554     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829592     Document Type: Review

References (63)

1. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989;52:1121-1127
2. Mantegazza R, Baggi F, Antozzi C, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 2003;998:413-423
3. Phillips LH II. The epidemiology of myasthenia gravis. Ann N Y Acad Sci 2003;998:407-412
4. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48:1246-1252
5. Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987;505:526-538
6. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value-1975. Neurology 1998;51:933
7. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126(Pt 10):2304-2311
8. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-1980
9. Engel AG, Ohno K, Sine SM. Sleuthing molecular targets for neurological diseases at the neuromuscular junction. Nat Rev Neurosci 2003;4:339-352
10. Engel AG, Ohno K, Sine SM. Congenital myasthenic syndromes: progress over the past decade. Muscle Nerve 2003;27:4-25
11. Banwell BL, Russel J, Fukudome T, Shen XM, Stilling G, Engel AG. Myopathy, myasthenic syndrome, and epidermolysis bullosa simplex due to plectin deficiency. J Neuropathol Exp Neurol 1999;58:832-846
12. Engel AG, Ohno K, Shen XM, Sine SM. Congenital myasthenic syndromes: multiple molecular targets at the neuromuscular junction. Ann N Y Acad Sci 2003;998:138-160
13. Ohno K, Tsujino A, Brengman JM, et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci USA 2001;98:2017-2022
14. Maselli RA, Chen D, Mo D, Bowe C, Fenton G, Wollmann RL. Choline acetyltransferase mutations in myasthenic syndrome due to deficient acetylcholine resynthesis. Muscle Nerve 2003;27:180-187
15. Tsujino A, Maertens C, Ohno K, et al. Myasthenic syndrome caused by mutation of the SCN4A sodium channel. Proc Natl Acad Sci USA 2003;100:7377-7382
16. Willmann R, Fuhrer C. Neuromuscular synaptogenesis: clustering of acetylcholine receptors revisited. Cell Mol Life Sci 2002;59:1296-1316
17. Ramarao MK, Bianchetta MJ, Lanken J, Cohen JB. Role of rapsyn tetratricopeptide repeat and coiled-coil domains in self-association and nicotinic acetylcholine receptor clustering. J Biol Chem 2001;276:7475-7483
18. Huebsch KA, Maimone MM. Rapsyn-mediated clustering of acetylcholine receptor subunits requires the major cytoplasmic loop of the receptor subunits. J Neurobiol 2003;54:486-501
19. Ohno K, Sadeh M, Blatt I, Brengman JM, Engel AG. E-box mutations in the RAPSN promoter region in eight cases with congenital myasthenic syndrome. Hum Mol Genet 2003;12:739-748
20. Ohno K, Engel AG, Shen XM, et al. Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome. Am J Hum Genet 2002;70:875-885
21. Burke G, Cossins J, Maxwell S, et al. Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset phenotypes. Neurology 2003;61:826-828
22. Dunne V, Maselli RA. Identification of pathogenic mutations in the human rapsyn gene. J Hum Genet 2003;48:204-207
23. Maselli RA, Dunne V, Pascual-Pascual SI, et al. Rapsyn mutations in myasthenic syndrome due to impaired receptor clustering. Muscle Nerve 2003;28:293-301
24. Muller JS, Mildner G, Muller-Felber W, et al. Rapsyn N88K is a frequent cause of congenital myasthenic syndromes in European patients. Neurology 2003;60:1805-1810
25. Richard P, Gaudon K, Andreux F, et al. Possible founder effect of rapsyn N88K mutation and identification of novel rapsyn mutations in congenital myasthenic syndromes. J Med Genet 2003;40:e81
26. Harper C. Congenital myasthenic syndromes. In: Brown W, Bolton C, Aminoff M, eds. Neuromuscular Function and Disease, 1st ed. Philadelphia: WB Saunders; 2002:1687-1696
27. Harper CM, Engel AG. Treatment of 31 congenital myasthenic syndrome patients with 3,4-diaminopyridine. Neurology 2000;54:A395
28. Engel AG, Ohno K, Sine SM. The spectrum of congenital myasthenic syndromes. Mol Neurobiol 2002;26:347-367
29. Croxen R, Hatton C, Shelley C, et al. Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes. Neurology 2002;59:162-168
30. Fukudome T, Ohno K, Brengman JM, Engel AG. Quinidine normalizes the open duration of slow-channel mutants of the acetylcholine receptor. Neuroreport 1998;9:1907-1911
31. Harper CM, Engel AG. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann Neurol 1998;43:480-484
32. Engel AG, Ohno K, Milone M, et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol Genet 1996;5:1217-1227
33. Gomez CM, Maselli R, Gundeck JE, et al. Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction. J Neurosci 1997;17:4170-4179
34. Milone M, Wang HL, Ohno K, et al. Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor alpha subunit. J Neurosci 1997;17:5651-5665
35. Ohno K, Quiram PA, Milone M, et al. Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor epsilon subunit gene: identification and functional characterization of six new mutations. Hum Mol Genet 1997;6:753-766
36. Harper CM, Fukodome T, Engel AG. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 2003;60:1710-1713
37. Sine SM, Wang HL, Ohno K, Shen XM, Lee WY, Engel AG. Mechanistic diversity underlying fast channel congenital myasthenic syndromes. Ann N Y Acad Sci 2003;998:128-137
38. Ohno K, Wang HL, Milone M, et al. Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit. Neuron 1996;17:157-170
39. Brownlow S, Webster R, Croxen R, et al. Acetylcholine receptor delta subunit mutations underlie a fast-channel myasthenic syndrome and arthrogryposis multiplex congenita. J Clin Invest 2001;108:125-130
40. Shen XM, Ohno K, Fukudome T, et al. Congenital myasthenic syndrome caused by low-expressor fast-channel AChR delta subunit mutation. Neurology 2002;59:1881-1888
41. Ohno K, Engel AG, Brengman JM, et al. The spectrum of mutations causing end-plate acetylcholinesterase deficiency. Ann Neurol 2000;47:162-170
42. Bon S, Ayon A, Leroy J, Massoulie J. Trimerization domain of the collagen tail of acetylcholinesterase. Neurochem Res 2003;28:523-535
43. Ishigaki K, Nicolle D, Krejci E, et al. Two novel mutations in the COLQ gene cause endplate acetylcholinesterase deficiency. Neuromuscul Disord 2003;13:236-244
44. Hutchinson DO, Walls TJ, Nakano S, et al. Congenital endplate acetylcholinesterase deficiency. Brain 1993;116 (Pt 3):633-653
45. Kohara N, Lin TS, Fukudome T, et al. Pathophysiology of weakness in a patient with congenital end-plate acetylcholinesterase deficiency. Muscle Nerve 2002;25:585-592
46. Breningstall GN, Kurachek SC, Fugate JH, Engel AG. Treatment of congenital endplate acetylcholinesterase deficiency by neuromuscular blockade. J Child Neurol 1996;11:345-346
47. Milone M, Engel AG. Block of the endplate acetylcholine receptor channel by the sympathomimetic agents ephedrine, pseudoephedrine, and albuterol. Brain Res 1996;740:346-352
48. Conomy JP, Levinsohn M, Fanaroff A. Familial infantile myasthenia gravis: a cause of sudden death in young children. J Pediatr 1975;87:428-430
49. Kraner S, Laufenberg I, Strassburg HM, Sieb JP, Steinlein OK. Congenital myasthenic syndrome with episodic apnea in patients homozygous for a CHAT missense mutation. Arch Neurol 2003;60:761-763
50. Schmidt C, Abicht A, Krampfl K, et al. Congenital myasthenic syndrome due to a novel missense mutation in the gene encoding choline acetyltransferase. Neuromuscul Disord 2003;13:245-251
51. Mora M, Lambert EH, Engel AG. Synaptic vesicle abnormality in familial infantile myasthenia. Neurology 1987;37:206-214
52. Matthes JW, Kenna AP, Fawcett PR. Familial infantile myasthenia: a diagnostic problem. Dev Med Child Neurol 1991;33:924-929
53. Zammarchi E, Donati MA, Masi S, Sarti A, Castelli S. Familial infantile myasthenia: a neuromuscular cause of respiratory failure. Childs Nerv Syst 1994;10:347-349
54. Baptist EC, Landes RV, Sturman JK Jr. Familial infantile myasthenia gravis: a preventable cause of sudden death. South Med J 1985;78:201-202
55. Walls TJ, Engel AG, Nagel AS, Harper CM, Trastek VF. Congenital myasthenic syndrome associated with paucity of synaptic vesicles and reduced quantal release. Ann N Y Acad Sci 1993;681:461-468
56. Albers JW, Faulkner JA, Dorovini-Zis K, Barald KF, Must RE, Ball RD. Abnormal neuromuscular transmission in an infantile myasthenic syndrome. Ann Neurol 1984;16:28-34
57. Bady B, Chauplannaz G, Carrier H. Congenital Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1987;50:476-478
58. Maselli RA, Kong DZ, Bowe CM, et al. Presynaptic congenital myasthenic syndrome due to quantal release deficiency. Neurology 2001;57:279-289
59. Sine SM, Ohno K, Bouzat C, et al. Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 1995;15:229-239
60. Croxen R, Newland C, Beeson D, et al. Mutations in different functional domains of the human muscle acetylcholine receptor alpha subunit in patients with the slow-channel congenital myasthenic syndrome. Hum Mol Genet 1997;6:767-774
61. Ohno K, Engel AG. Congenital myasthenic syndromes: genetic defects of the neuromuscular junction. Curr Neurol Neurosci Rep 2002;2:78-88
62. Gomez CM, Maselli RA, Vohra BP, et al. Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms. Ann Neurol 2002;51:102-112
63. Shen XM, Ohno K, Tsujino A, et al. Mutation causing severe myasthenia reveals functional asymmetry of AChR signature cystine loops in agonist binding and gating. J Clin Invest 2003;111:497-505